Search

Search Constraints

You searched for: Author/Creator Defer, Gilles

Search Results

1. 136 NOVA primary results randomised controlled study of natalizumab Q6W versus continued Q4W treatment for MS. Issue 9 (12th August 2022)

2. BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. (September 2021)

3. CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. (6th December 2016)

4. CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. (6th December 2016)

6. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. (13th August 2019)

7. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. (23rd February 2016)

8. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Issue 7 (July 2022)

9. Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?. (July 2019)

10. Determinants of therapeutic lag in multiple sclerosis. (October 2021)